Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) Overview 6 Therapeutics Development 7 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Products under Development by Stage of Development 7 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Products under Development by Therapy Area 8 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Products under Development by Indication 9 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Products under Development by Companies 12 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Products under Development by Universities/Institutes 14 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 20 Bayer AG 20 eFFECTOR Therapeutics, Inc. 21 Eli Lilly and Company 22 Selvita S.A. 23 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Drug Profiles 24 BAY-1143269 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 cercosporamide - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 eFT-508 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 ETC-027 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 ETC-17804452 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 ETC-219 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 SEL-201 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 SLV-2436 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Dormant Projects 34 MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Featured News & Press Releases 35 Mar 18, 2016: eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting 35 Jun 19, 2015: Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment 35 Jan 06, 2015: eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38

List of Tables Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Bayer AG, H1 2016 20 Pipeline by eFFECTOR Therapeutics, Inc., H1 2016 21 Pipeline by Eli Lilly and Company, H1 2016 22 Pipeline by Selvita S.A., H1 2016 23 Dormant Projects, H1 2016 34 List of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Actions, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19

Bayer AG eFFECTOR Therapeutics, Inc. Eli Lilly and Company Selvita S.A.